Results 141 to 150 of about 2,657,261 (342)

The impact of multidrug therapy on the epidemiological pattern of leprosy in Juiz de Fora, Brazil

open access: yesCadernos de Saúde Pública, 2000
We investigated the impact of multidrug therapy (MDT) on the epidemiological pattern of leprosy in Juiz de Fora, Brazil, from 1978 to 1995. Evaluation of 1,283 medical charts was performed according to the treatment regimen used in two different periods.
Soares Luzivander S.   +6 more
doaj  

Combination Drug Therapy for the Management of Alzheimer’s Disease

open access: yesРоссийский журнал гериатрической медицины
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases worldwide. It is the leading cause of dementia in both older and oldest old population.
N. G. Dudchenko, E. A. Mkhitaryan
doaj   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Expanding role for single-pill combination drug therapy in the initial treatment of hypertension? [PDF]

open access: yesJ Clin Hypertens (Greenwich), 2021
Li Y   +7 more
europepmc   +1 more source

Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations [PDF]

open access: yes, 2017
By use of simulations we imputed human immunodeficiency virus type 1 drug resistance incidence to protease inhibitor-based or nonnucleoside reverse-transcriptase inhibitor-based combination therapy.
Battegay, Manuel   +13 more
core  

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

open access: yesMolecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy